PMID- 28902678
OWN - NLM
STAT- MEDLINE
DCOM- 20170925
LR  - 20180223
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
VI  - 76
IP  - 2
DP  - 2017 Oct 1
TI  - Brief Report: High Need to Switch cART or Comedication With the Initiation of
      DAAs in Elderly HIV/HCV-Coinfected Patients.
PG  - 193-199
LID - 10.1097/QAI.0000000000001488 [doi]
AB  - BACKGROUND: To describe the use of nonantiretroviral comedication and combination
      antiretroviral therapy (cART) in patients coinfected with HIV/hepatitis C virus
      (HCV) and to predict the potential for drug-drug interactions (DDIs) with
      direct-acting antivirals (DAAs) against HCV. METHODS: This is a retrospective,
      cross-sectional study, using the Dutch, nationwide ATHENA observational HIV
      cohort database. All patients with a known HIV/HCV coinfection on January 1,
      2015, were included. Comedication and cART registered in the database were
      listed. The potential for DDIs between DAAs and comedication/cART were predicted 
      using http://hep-druginteractions.org. DDIs were categorized as: (1) no
      clinically relevant DDI; (2) possible DDI; (3) contraindication; or (4) no
      information available. RESULTS: We included 777 patients of whom 488 (63%) used
      nonantiretroviral comedication. At risk for a category 2/3 DDI with
      nonantiretroviral comedications were 299 patients (38%). Most DDIs were predicted
      with paritaprevir/ritonavir, ombitasvir +/- dasabuvir (47% of the drugs) and
      least with grazoprevir/elbasvir (11% of the drugs). Concerning cART,
      daclatasvir/sofosbuvir is the most favorable combination as no cART is
      contraindicated with this combination. In genotype 1/4 patients,
      grazoprevir/elbasvir is least favorable as 75% of the patients must alter their
      cART. CONCLUSIONS: This study showed that comedication use in the aging HIV/HCV
      population is frequent and diverse. There is a high potential for DDIs between
      DAAs and comedication/cART.
FAU - Smolders, Elise J
AU  - Smolders EJ
AD  - *Department of Pharmacy, Radboud Institute of Health Sciences (RIHS) and Radboud 
      university medical center, Nijmegen, the Netherlands; daggerHIV Monitoring
      Foundation, Amsterdam, the Netherlands; double daggerDepartment of Pharmacy,
      University Medical Center Utrecht, Utrecht, the Netherlands; section
      signDepartment of Internal Disease and Infectious Diseases, Radboud university
      medical center, Nijmegen, the Netherlands; ||Department of Internal Medicine and 
      Infectious Diseases, University Medical Center, Utrecht, the Netherlands;
      paragraph signDepartment of Internal Medicine and Infectious Diseases, OLVG,
      Amsterdam, the Netherlands; #Department of Internal Medicine and Infectious
      Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands;
      **Academic Medical Center, Division of Infectious Diseases, and Center for
      Infection and Immunity Amsterdam (CINIMA), Amsterdam, the Netherlands; and
      daggerdaggerDepartment of Global Health and Amsterdam Institute for Global Health
      and Development, Academic Medical Center of the University of Amsterdam,
      Amsterdam, the Netherlands.
FAU - Smit, Colette
AU  - Smit C
FAU - T M M de Kanter, Clara
AU  - T M M de Kanter C
FAU - Dofferiiof, Anton S M
AU  - Dofferiiof ASM
FAU - Arends, Joop E
AU  - Arends JE
FAU - Brinkman, Kees
AU  - Brinkman K
FAU - Rijnders, Bart
AU  - Rijnders B
FAU - van der Valk, Marc
AU  - van der Valk M
FAU - Reiss, Peter
AU  - Reiss P
FAU - Burger, David M
AU  - Burger DM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0
      (2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofu
      ran-5-yl)-1H-imidazole)
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzofurans)
RN  - 0 (Imidazoles)
RN  - 0 (Quinoxalines)
RN  - 8YE81R1X1J (MK-5172)
RN  - O3J8G9O825 (Ritonavir)
SB  - IM
SB  - X
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - Benzofurans/therapeutic use
MH  - Coinfection/*drug therapy
MH  - Combined Modality Therapy
MH  - Cross-Sectional Studies
MH  - Drug Interactions
MH  - Drug Therapy, Combination
MH  - HIV/drug effects
MH  - HIV Infections/*drug therapy
MH  - Hepacivirus/drug effects
MH  - Hepatitis C/*drug therapy
MH  - Humans
MH  - Imidazoles/therapeutic use
MH  - Middle Aged
MH  - Quinoxalines/therapeutic use
MH  - Retrospective Studies
MH  - Ritonavir/therapeutic use
MH  - Young Adult
EDAT- 2017/09/14 06:00
MHDA- 2017/09/26 06:00
CRDT- 2017/09/14 06:00
PHST- 2017/09/14 06:00 [entrez]
PHST- 2017/09/14 06:00 [pubmed]
PHST- 2017/09/26 06:00 [medline]
AID - 10.1097/QAI.0000000000001488 [doi]
AID - 00126334-201710010-00013 [pii]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):193-199. doi:
      10.1097/QAI.0000000000001488.